Overview

Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

Status:
Active, not recruiting

Trial end date:
2022-08-31

Target enrollment:

Participant gender:

Summary

Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction

Phase:

Phase 1

Details

Lead Sponsor:

VU University Medical Center

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab